These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20392387)

  • 21. Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis treated successfully with a combination of intravenous immunoglobulins and N-acetylcysteine.
    Claes P; Wintzen M; Allard S; Simons P; De Coninck A; Lacor P
    Eur J Intern Med; 2004 Jul; 15(4):255-258. PubMed ID: 15288682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxic epidermal necrolysis and intravenous immunoglobulin: a review.
    Trent J; Halem M; French LE; Kerdel F
    Semin Cutan Med Surg; 2006 Jun; 25(2):91-3. PubMed ID: 16908399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin.
    Sidwell RU; Swift S; Yan CL; Porter W; Thompson EM; Clark JA; Bunker CB
    Int J Clin Pract; 2003 Sep; 57(7):643-5. PubMed ID: 14529073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxic epidermal necrolysis (TEN) Lyell's syndrome.
    Sehgal VN; Srivastava G
    J Dermatolog Treat; 2005; 16(5-6):278-86. PubMed ID: 16428146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo].
    Pitche P; Mouzou T; Padonou C; Tchangai-Walla K
    Med Trop (Mars); 2005 Sep; 65(4):359-62. PubMed ID: 16548490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin.
    Simeone F; Rubio ER
    J La State Med Soc; 2003; 155(5):266-9. PubMed ID: 14748489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre.
    Lee HY; Lim YL; Thirumoorthy T; Pang SM
    Br J Dermatol; 2013 Dec; 169(6):1304-9. PubMed ID: 24007192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis.
    Paquet P; Kaveri S; Jacob E; Pirson J; Quatresooz P; Piérard GE
    Exp Dermatol; 2006 May; 15(5):381-6. PubMed ID: 16630079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Kardaun SH; Jonkman MF
    Acta Derm Venereol; 2007; 87(2):144-8. PubMed ID: 17340021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe cutaneous adverse reactions to drugs.
    Chia FL; Leong KP
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.
    Chan HL; Stern RS; Arndt KA; Langlois J; Jick SS; Jick H; Walker AM
    Arch Dermatol; 1990 Jan; 126(1):43-7. PubMed ID: 2404462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
    Murata J; Abe R; Shimizu H
    J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study.
    Mangla K; Rastogi S; Goyal P; Solanki RB; Rawal RC
    Indian J Dermatol Venereol Leprol; 2005; 71(6):398-400. PubMed ID: 16394480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
    Sane SP; Bhatt AD
    J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Toxic epidermal necrolysis. Therapy in ICU with intravenous immunoglobulins in a case].
    Andresen M; Boghero Y; Molgó M; Dougnao A; Díaz O
    Rev Med Chil; 2000 Dec; 128(12):1343-8. PubMed ID: 11227243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical guidelines for the management of toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Fromowitz JS; Ramos-Caro FA; Flowers FP;
    Int J Dermatol; 2007 Oct; 46(10):1092-4. PubMed ID: 17910723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome.
    Kim DH; Yoon KC; Seo KY; Lee HS; Yoon SC; Sotozono C; Ueta M; Kim MK
    Ophthalmology; 2015 Feb; 122(2):254-64. PubMed ID: 25262319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stevens-Johnson syndrome and toxic epidermal necrolysis: consequence of treatment of an emerging pathogen.
    Mistry RD; Schwab SH; Treat JR
    Pediatr Emerg Care; 2009 Aug; 25(8):519-22. PubMed ID: 19687711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
    Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
    Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.